argenx SE (fra:1AEA) Share Price

Company Profile

Business description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Contact
Laarderhoogtweg 25
AmsterdamNH1101EB
NLD
T: +31 107038441
E: [email protected]
https://www.argenx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,148

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,073.98	45.70	0.57%
DAX 40	23,154.57	167.75	0.73%
Dow JONES (US)	41,841.63	353.44	0.85%
FTSE 100	8,680.29	47.96	0.56%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,808.66	54.58	0.31%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,154.23	11.91	-0.10%
S&P 500	5,675.12	36.18	0.64%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%